Statin use in adults at high risk of cardiovascular disease mortality: Cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA)

BMJ Open

Volumn 5, Issue 7, 2015, Pages

  Murphy, Catriona ^a   Bennett, Kathleen ^a   Fahey, Tom ^b   Shelley, Emer ^c   Graham, Ian ^d   Kenny, Rose Anne ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Department of General Practice HRB Centre for Primary Care Research Royal College of Srgons Ireland Medical School   (Ireland)

^c HEALTH SERVICE EXECUTIVE   (Ireland)

^d ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COMMUNITY LIVING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PRIMARY PREVENTION; RISK ASSESSMENT; SECONDARY PREVENTION; SEX DIFFERENCE; TRANSIENT ISCHEMIC ATTACK; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; HYPERCHOLESTEROLEMIA; IRELAND; PROTOCOL COMPLIANCE; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; IRELAND; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION;

EID: 84937197924     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-008017     Document Type: Article

References (52)

1. World Health Organization. Global Health Estimates 2014 Summary Tables Deaths by Cause, Age and Sex, 2000-2012. Secondary Global Health Estimates 2014 Summary Tables Deaths by Cause, Age and Sex, 2000-2012. 2014. http://www.who.int/healthinfo/global-burden-disease/estimates/en/index1.html
2. Department of Health. Health in Ireland: key trends 2012. Dublin: Department of Health, 2012.
3. Perk J, De Backer G, Gohlke H, et al 'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33:2126.
4. Baigent C, Keech A, Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
5. Nicholls SJ, Ballantyne CM, Barter P.J., et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365:2078-87.
6. Nissen SE, Nicholls SJ, Sipahi I, et al Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the asteroid trial. JAMA 2006; 295:1556-65.
7. Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis 2014; 24:1057-66.
8. Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769-818.
9. Taylor F, Ward K, Moore T.H., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011; (1): CD004816.
10. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. London: National Institute for Health and Clinical Excellence, 2008.
11. Stone NJ, Robinson J, Lichtenstein A.H., et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 129(25 Suppl 2):S1-45.
12. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (suppl 2):E1-40.
13. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
14. Whelan BJ. RANSAM: a national random sampling design for Ireland. Econ Soc Rev 1979; 10:169-74.
15. Cronin H, O'Regan C, Finucane C, et al Health and aging: development of The Irish Longitudinal Study on Ageing health assessment. J Am Geriatr Soc 2013; 61:S269-78.
16. Richardson K, Kenny RA, Peklar J, et al Agreement between patient interview data on prescription medication use and pharmacy records in those aged older than 50years varied by therapeutic group and reporting of indicated health conditions. J Clin Epidemiol 2013; 66:1308-16.
17. Martin SS, Blaha MJ, Elshazly M.B., et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol 2013; 62:732-9.
18. Central Statistics Office. StatBank CD211: enumerated population by sex age group and census year. Cork: CSO, 2012.
19. Cooney MT, Kotseva K, Dudina A., et al. Determinants of risk factor control in subjects with coronary heart disease: a report from the EUROASPIRE III investigators. Eur J Prev Cardiol 2013; 20:686-91.
20. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2015 [Epub ahead of print 16 Feb 2015].
21. Alabbadi I, Crealey G, Turner K., et al. Statin prescribing in Northern Ireland and England pre and post introduction of the quality and outcomes framework. Pharm World Sci 2010; 32:43-51.
22. Mindell J, Craig R, eds. Health survey of England 2011: health, social care and lifestyles, chapter 2 cardiovascular disease. NatCen Social Research, 2011.
23. Kotseva K, Jennings CS, Turner E.L., et al. ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK. Heart 2012; 98:865-71.
24. Fitzpatrick P, Fitz-Simon N, Lonergan M., et al. Heartwatch: the effect of a primary care-delivered secondary prevention programme for cardiovascular disease. Eur J Cardiovasc Prev Rehabil 2011; 18:129-35.
25. Bennett K, Jennings S, Collins C., et al. Heartwatch: a secondary prevention progamme in primary care in Ireland. Eur J Cardiovasc Prev Rehabil 2008; 15:651-6.
26. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-59.
27. Taylor F, Huffman MD, Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; (1):CD004816.
28. Abramson JD, Rosenberg HG, Jewell N, et al Should people at low risk of cardiovascular disease take a statin? BMJ 2013; 347:f6123.
29. Brugts JJ, Yetgin T, Hoeks S.E., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338:b2376.
30. National Institute for Health and Care Excellence. Lipid Modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE clinical guideline 181. NICE clinical guideline 181. National Institute for Health and Care Excellence, 2014.
31. Fenton K, Kelly MP, Newton J, et al NHS Health Check our approach to the evidence. Local Government Association, NICE, NHS England, 2013.
32. Krogsbøll L.T., Jørgensen KJ, Larsen CG, et al. General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. BMJ 2012; 345:e7191.
33. Jørgensen T, Jacobsen R.K., Toft U., et al. Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ 2014; 348:g3617.
34. Ho PM, Bryson C, Rumsfeld JS Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119:3028-35.
35. Jackevicius CA, Mamdani M, Tu JV Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288:462-7.
36. Rodriguez F, Cannon CP, Steg P.G., et al. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. Clin Cardiol 2013; 36:721-7.
37. Auer J, Sinzinger H, Franklin B., et al. Muscle- and skeletal-related side-effects of statins: tip of the iceberg? Eur J Prev Cardiol 2014 [Epub ahead of print 17 Sep 2014].
38. Gupta R, Islam S, Mony P., et al. Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: the PURE study. Eur J Prev Cardiol 2014 [Epub ahead of print 18 Jun 2015].
39. Bruckert E, Hayem G, Dejager S., et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 2005; 19:403-14.
40. Nolan A, Nolan B. Eligibility for free GP care, "need" and GP visiting in Ireland. Eur J Health Econ 2008; 9:157-63.
41. Murphy CM, Kearney PM, Shelley E.B., et al. Hypertension prevalence, awareness, treatment and control in the over 50s in Ireland: evidence from The Irish Longitudinal Study on Ageing. J Public Health (Oxf) 2015 [Epub ahead of print 28 Apr 2015].
42. Richardson K, Kenny RA, Bennett K. The effect of free health care on polypharmacy: a comparison of propensity score methods and multivariable regression to account for confounding. Pharmacoepidemiol Drug Saf 2014; 23:656-65.
43. Murphy C, Moore P, Mc Hugh S, Health and social care utilisation. In: Nolan A, O'Regan C, Dooley C, et al. eds. The over 50s in a changing Ireland: economic circumstances, health and well-being. Dublin: The Irish Longitudinal Study on Ageing, 2014:124-52.
44. Zannad F, Dallongeville J, Macfadyen R.J., et al. Prevention of cardiovascular disease guided by total risk estimations - challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Eur J Prev Cardiol 2012; 19:1454-64.
45. Graham IM, Stewart M, Hertog MG Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil 2006; 13:839-45.
46. Reiner Z, Sonicki Z, Tedeschi-Reiner E. Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis 2010; 213:598-603.
47. Dallongeville J, Banegas JR, Tubach F, et al Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prev Cardiol 2012; 19:541-50.
48. Hobbs FD, Jukema JW, Da Silva PM, et al. Barriers to cardiovascular disease risk scoring and primary prevention in Europe. QJM 2010; 103:727-39.
49. Kearney PM, O'Regan C, Cronin H, et al Effect of fasting on participation in clinical research among older people. Eur Geriatr Med 2011; 2:187-9.
50. Doran B, Guo Y, Xu J., et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation 2014; 130:546-53.
51. Frewen J, Finucane C, Cronin H., et al. Factors that influence awareness and treatment of atrial fibrillation in older adults. QJM 2013; 106:415-24.
52. Mosca I, Bhuachalla BN, Kenny RA Explaining significant differences in subjective and objective measures of cardiovascular health: evidence for the socioeconomic gradient in a population-based study. BMC Cardiovas Disord 2013; 13:64.